MacroGenics to Present at the Stifel 2014 Healthcare

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
MacroGenics to Present at the Stifel 2014 Healthcare Conference

ROCKVILLE, Md., Nov. 12, 2014 (GLOBE NEWSWIRE) -- ROCKVILLE, Md., November 12, 2014 - MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig, M.D., Ph.D., President and CEO will present at the Stifel 2014 Healthcare Conference in New York, NY. The presentation will take place on Tuesday, November 18, 2014 at 10:55 a.m. Eastern Time.

A live webcast of MacroGenics' presentation may be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm . MacroGenics will maintain an archived replay of the webcast on its website for 30 days after the conference.

About MacroGenics, Inc.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The Company generates its pipeline of product candidates from its proprietary suite of next-generation antibody-based technology platforms.  The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com.  ; MacroGenics is a registered trademark of MacroGenics, Inc.  

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, milestone or opt-in payments from the Company's collaborators, the Company's future expectations and plans and prospects and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risk factors described in the Company's filings with the Securities and Exchange Commission, including those discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2014 and the subsequent Quarterly Reports on Form 10-Q. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

###

CONTACT: Jim Karrels, Vice President, CFO MacroGenics, Inc. 1-301-251-5172, info@macrogenics.com Karen Sharma, Vice President MacDougall Biomedical Communications 1-781-235-3060, ksharma@macbiocom.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Yoodli's No. 9 Ranking Signals Enterprise AI Traction

Updated Category News Views 35

Ninth place can be easy to dismiss until you notice the company is sitting near the top of a 500-name growth list. Yoodli's No. 9 position on Deloitte's 2026 Technology Fast 500 is a meaningful signal that its AI-based coaching and workforce-skills pitch is getting traction inside large organizations. It is not a revenue disclosure, it is not a valuation marker, and...

Continue Reading
TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 96

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading
Epsium's Inventory Pile Looms Over Weak First Half

Updated Category News Views 73

A warehouse full of bottles is not a balance-sheet fortress when buyers are backing away. Epsium Enterprise’s first-half 2026 report is a rough read: revenue collapsed 51.8% to $1.47 million, gross profit fell to $175,353, and cash slid to $612,761 at June 30. This is not a subtle slowdown. Macau’s premium Chinese-liquor market has been weak on both demand and...

Continue Reading
Three Cash Buyouts Draw Fresh Shareholder Scrutiny

Updated Category News Views 149

Three cash-price tags landed on the tape with a lawyerly asterisk attached: are public holders actually getting a fair shake? On November 18, 2026, Halper Sadeh LLC said it was investigating proposed sales involving Surgery Partners, Braze and CCC Intelligent Solutions. That is not a finding of misconduct, and investors ought to keep that distinction bolted firmly to the...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 45

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
Precision Metal Forming Is Industry's Quiet Backbone

Updated Category News Views 88

A fraction of a millimeter can turn a perfectly good industrial part into an expensive headache. That unglamorous reality sits at the center of Michele Caulfield's discussion of precision metal forming for HelloNation, and it deserves more attention than it usually gets. Investors watching manufacturing tend to chase flashy automation headlines, big aerospace orders, or...

Continue Reading
Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 156

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
Tim Hortons Bets on ELF Cheer for U.S. Holiday Visits

Updated Category News Views 23

Nothing says holiday restaurant marketing quite like putting spaghetti-shaped whipped topping on hot chocolate and trusting a 2003 movie to do the selling. Tim Hortons is rolling out an ELF-inspired menu at participating U.S. locations starting November 18, 2026, pairing the chain with Warner Bros. Consumer Products and mining Buddy the Elf's sugar-fueled world for a...

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 221

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 293

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading

Top 5 Most Recently Viewed Articles

Bouygues Announces Updated Share and Voting Rights Information

Updated Category News Views 382

Monthly Disclosure of Shares and Voting Rights by Bouygues The importance of transparency in corporate governance cannot be overstated, and Bouygues, a prominent player in the construction and telecommunications sectors, prioritizes this. Presenting clear, timely, and precise updates regarding shares and voting rights reflects the company’s commitment to its...

Continue Reading
Capital Raises KT&G Stake to 8.2% Amid Global Gains

Updated Category News Views 37

Capital Research Strengthens Hold in KT&G Things have been heating up in Seoul. Capital Research and Management Company, a heavyweight in fund management, has just pushed its stake in KT&G up to 8.22%. That's a leap from the earlier 5.61% in May, and 7.21% by June. These guys manage a whopping $3.3 trillion in assets—so when they make a move, others tend to perk up and...

Continue Reading
Butterfly Network and Rutgers Study Show Impact of POCUS

Updated Category News Views 182

Revolutionizing Hospital Care with POCUS Technology BURLINGTON, Mass. & NEW YORK-- Butterfly Network, Inc. (NYSE: BFLY), a pioneering digital health company, has launched a significant study in collaboration with Rutgers Robert Wood Johnson Medical School. This research emphasizes the transformative influence of point-of-care ultrasound (POCUS) technology on patient...

Continue Reading
Staying Ahead of the Curve: Why Trading Compliance Is Now a Strategic Advantage

Updated Category Investing Views 1309

In today’s fast-evolving financial landscape, trading compliance has become more than just a regulatory requirement—it’s a defining pillar of strategic success. As regulators tighten their grip and technology uncovers previously invisible risks, firms that embrace advanced compliance measures are not only staying protected but also gaining a competitive edge....

Continue Reading
Key Insights Into the Expanding Hydrogen Storage Sector

Updated Category News Views 180

The Rise of the Hydrogen Energy Storage Market The global hydrogen energy storage market is on the verge of significant growth, with projections indicating a remarkable CAGR of 72.1%, potentially reaching a substantial $23.7 billion by the end of 2029. This surge reflects a shift toward cleaner energy solutions, driven by advancements in technology, policy support, and a...

Continue Reading